Jefferies on Moderna (MRNA): '2026 Remains a Covid Story'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Hold rating and $30.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "Per an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
